A. Qin

432 total citations · 1 hit paper
20 papers, 286 citations indexed

About

A. Qin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, A. Qin has authored 20 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in A. Qin's work include HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Gastric Cancer Management and Outcomes (5 papers). A. Qin is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Gastric Cancer Management and Outcomes (5 papers). A. Qin collaborates with scholars based in United States, China and Belgium. A. Qin's co-authors include Jasmeet Singh, Shanu Modi, Corina Taitt, Charles A. Powell, Hiroji Iwata, D. Ross Camidge, Salvatore Siena, Shunji Takahashi, Egbert F. Smit and Norah J. Shire and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Clinical Pharmacology & Therapeutics.

In The Last Decade

A. Qin

17 papers receiving 284 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

2022 121 citations Charles A. Powell, Shanu Modi et al. ESMO Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Qin United States	8	208	149	88	35	32	20	286
Lea Lowenfeld United States	9	251 1.2×	55 0.4×	51 0.6×	23 0.7×	72 2.3×	19	362
Myoung Won Son South Korea	10	101 0.5×	101 0.7×	47 0.5×	25 0.7×	68 2.1×	35	261
Ignacio Tusquets Spain	9	131 0.6×	110 0.7×	21 0.2×	50 1.4×	50 1.6×	16	252
Mariela A. Blum Murphy United States	9	158 0.8×	134 0.9×	52 0.6×	39 1.1×	25 0.8×	30	258
Lyudmila Zhukova Russia	7	201 1.0×	122 0.8×	35 0.4×	6 0.2×	58 1.8×	89	287
Hazel Lote United Kingdom	8	116 0.6×	78 0.5×	30 0.3×	8 0.2×	37 1.2×	17	198
Miao Huang China	9	184 0.9×	159 1.1×	33 0.4×	10 0.3×	61 1.9×	17	298
Carlene L. Chun United States	6	212 1.0×	102 0.7×	23 0.3×	42 1.2×	45 1.4×	11	314
Ina Valeria Zurlo Italy	6	105 0.5×	89 0.6×	15 0.2×	12 0.3×	36 1.1×	24	191
Olga Barajas Chile	5	377 1.8×	331 2.2×	59 0.7×	120 3.4×	59 1.8×	13	554

Countries citing papers authored by A. Qin

Since Specialization

Citations

This map shows the geographic impact of A. Qin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Qin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Qin more than expected).

Fields of papers citing papers by A. Qin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Qin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Qin. The network helps show where A. Qin may publish in the future.

Co-authorship network of co-authors of A. Qin

This figure shows the co-authorship network connecting the top 25 collaborators of A. Qin. A scholar is included among the top collaborators of A. Qin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Qin. A. Qin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yu, Peng, Fubin Liu, Peng Wang, et al.. (2025). Association Between Volume, Intensity and Rhythm of Physical Activity Measured by Accelerometer and Risk of All‐Cause and Cause‐Specific Mortality in Individuals With MASLD. Alimentary Pharmacology & Therapeutics. 62(1). 48–58.

Yu, Peng, Peng Wang, Fubin Liu, et al.. (2025). Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study. Diabetes Obesity and Metabolism. 27(4). 1940–1949. 2 indexed citations

Liu, Fubin, Peng Yu, Peng Wang, et al.. (2024). Sex disparity in the association between metabolic-anthropometric phenotypes and risk of obesity-related cancer: a prospective cohort study. BMC Medicine. 22(1). 355–355.

Liu, Fubin, Linlin Chen, Peng Yu, et al.. (2024). EAT‐Lancet Diet Pattern, Genetic Predisposition, Inflammatory Biomarkers, and Risk of Lung Cancer Incidence and Mortality. Molecular Nutrition & Food Research. 68(19). e2400448–e2400448. 7 indexed citations

Yu, Peng, Fubin Liu, Peng Wang, et al.. (2024). Integrated analysis of microbiota and gut microbial metabolites in blood for breast cancer. mSystems. 9(11). e0064324–e0064324. 6 indexed citations

Verhoeven, Rob H.A., et al.. (2023). 1574P Trastuzumab deruxtecan versus ramucirumab and paclitaxel as second-line therapy for patients with her2-positive gastric or gastro-esophageal junction adenocarcinoma: A propensity score matched comparison. Annals of Oncology. 34. S878–S878.

Ku, Geoffrey Y., Maria Di Bartolomeo, Ian Chau, et al.. (2022). 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. Annals of Oncology. 33. S1100–S1100. 21 indexed citations

Powell, Charles A., Shanu Modi, Hiroji Iwata, et al.. (2022). Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 7(4). 100554–100554. 121 indexed citations breakdown →

Cutsem, Eric Van, Maria Di Bartolomeo, Ian Chau, et al.. (2021). LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Annals of Oncology. 32. S1332–S1332. 23 indexed citations

10.

Powell, Charles A., Shanu Modi, Hiroji Iwata, et al.. (2021). 92O Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd). Annals of Oncology. 32. S61–S62. 12 indexed citations

11.

Fuchs, Charles S., Javad Shahidi, Lijoy K. Mathew, A. Qin, & Eric Van Cutsem. (2020). P-184 A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology. 31. S150–S150. 1 indexed citations

12.

Powell, Charles A., D. Ross Camidge, Shanu Modi, et al.. (2020). 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Annals of Oncology. 31. S357–S358. 18 indexed citations

13.

Wagner, Andrew J., Hedy L. Kindler, Hans Gelderblom, et al.. (2016). A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Annals of Oncology. 28(3). 541–546. 44 indexed citations

14.

Tap, William D., Robin L. Jones, Bartosz Chmielowski, et al.. (2016). A randomized phase 1b/2 study evaluating the safety and efficacy of doxorubicin (dox) with or without olaratumab (IMC-3G3), a human anti–platelet-derived growth factor &agr; (pdgfr&agr;) monoclonal antibody, in advanced soft tissue sarcoma (sts). Annals of Oncology. 27. iv98–iv98. 2 indexed citations

15.

Martell, Robert E., E. Gabriela Chiorean, Hagop Youssoufian, et al.. (2011). Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.. Journal of Clinical Oncology. 29(15_suppl). TPS150–TPS150. 3 indexed citations

16.

Woll, Penella J., et al.. (2010). Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumours. Journal of Clinical Oncology. 21. 1 indexed citations

17.

Thompson, Dawn, Amita Patnaik, J. C. Bendell, et al.. (2010). A phase I dose-escalation study of IMGN388 in patients with solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 3058–3058. 15 indexed citations

18.

Bendell, Johanna C., Kraig Moore, A. Qin, et al.. (2010). 472 A phase I study of IMGN388, an antibody drug conjugate targeting av integrin, in patients with solid tumors. European Journal of Cancer Supplements. 8(7). 152–152. 5 indexed citations

19.

Woll, Penella J., et al.. (2008). 510 POSTER Phase I study of IMGN901 (BB-10901) in patients with CD56-positive solid tumours. European Journal of Cancer Supplements. 6(12). 162–162. 3 indexed citations

20.

Letrent, Stephen P., D A Noe, A. Qin, et al.. (2006). PI-13Pharmacokinetics and pharmacodynamics of a HER2 tyrosine kinase inhibitor CP-724714 in patients with advanced malignant HER2 positive solid tumors. Clinical Pharmacology & Therapeutics. 79(2). P10–P10. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact